Poster ID – **P0202**

LABORATOIRE A-DERMA

Tolerance and efficacy of a new emollient dedicated to the face containing Rhealba oat and *Helichrysum g.* in the long-term management of atopic dermatitis: an open-label, monocentric study

K. Bouyer[1], A. Brocario[2], V. Mengeaud[2], M.D. Thouvenin[1]

1. *R&D Department, Pierre Fabre Dermo-Cosmetics & Personal Care, Toulouse, France*
2. *Medical Department, Laboratoire Dermatologique A-DERMA, Pierre Fabre Dermo-Cosmetics & Personal Care, Lavaur, France*

Introduction & Objectives

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a significant impact on quality of life. Involvement of the face is very common and clinically significant, as facial skin is thinner, more exposed to environmental aggressors, and more visible, resulting in greater discomfort, stigmatization, and psychosocial burden for patients. The essential requirements for an emollient are safety, efficacy and good cosmetic acceptability, in order to ensure optimal compliance.


A new **gel cream emollient** with a light texture specifically dedicated to the face and containing **Rhealba oat** and *Helichrysum gymnocephalum* has been developed.

The aim of this study was to assess the **long-term tolerability and efficacy** of this new emollient product in subjects with **atopic dermatitis on the face.**

Materials & Methods

STUDY DESIGN

Monocentric open-label study



2 APPLICATIONS / DAY (morning & evening)

** For Pruritus, Discomfort & DLQI assessments*

MAIN INCLUSION CRITERIA

Atopic dermatitis on the face with:

- Local (L)-SCORAD : 3 to 8 inclusive
- **Xerosis intensity ≥1** (mild) (0–3 scale)
- **Pruritus intensity ≥2** (average over the last 3 days, 0–10 numeric rating scale, NRS)
- **Pruritus intensity ≥2** (at the time of the visit, 0–10 numeric rating scale, NRS)
- **Discomfort sensation: ≥ 3** (0–10 numeric rating scale, NRS)
- At least **1 peak of dryness & itching per month** in the 3 months prior to the inclusion visit

EVALUATIONS

- ATOPIC DERMATITIS SEVERITY (Local-SCORAD and Sub-parameters)
- PRURITUS (NRS)
- DISCOMFORT SENSATIONS (NRS)
- DERMATOLOGICAL TOLERABILITY
- QUALITY OF LIFE Dermatology Life Quality Index (DLQI)
- PEAKS OF DRYNESS & ITCHING* (by the subject)
- GLOBAL EFFICACY*

** Evaluated only at D85*


POPULATION

- **33** adults presenting facial atopic dermatitis
- **18–67 years** mean age 41 years
- **91% / 9%** women / men
- **3% / 73% / 24%** phototype I / II / III


Results

Pruritus Intensity

Mean intensity over the last 3 days



Immediate effect




NUMERIC RATING SCALE (NRS): 0 (no itch) TO 10 (worst imaginable itch)

D1T0: Before 1st product application
D1Timm: Immediately after product application

Mean ± SEM
*** p<0.001 vs baseline (D1)


AD severity

L-SCORAD




L-SCORAD (0 TO 18)

Erythema




Xerosis



SCORING: from 0 (absent) – 3 (severe) by the investigator;
Mean ± SEM / *** p<0.001 vs baseline (D1)

Discomfort sensation




NUMERIC RATING SCALE (NRS): 0 (no discomfort) TO 10 (worst imaginable discomfort)

D1T0: Before 1st product application
D1Timm: Immediately after product application


Mean ± SEM
*** p<0.001 vs baseline (D1)

DLQI



SCORING: from 0 – 30 by the subject ;
Mean ± SEM / *** p<0.001 vs baseline (D1)

Peaks of dryness & itching



No peak of dryness & itching was reported during the study.

Mean ± SEM
*** p<0.001

➔ **Clinical improvement maintained over the 3-month follow-up**

Global efficacy

After **3 months of use**


Global efficacy of the product judged as **'effective' to 'very effective'**:

- **by 97% of the subjects**
- **for 97% of subjects by the investigator**

Tolerability

Tolerance rated as **'very good'** by the dermatologist after **3 months** of twice daily use

Illustrative pictures



Female subject, 21 years old / best case based on clinical scoring Erythema - Standard lighting (Nikon D90)

Photo credits: *Pierre Fabre Dermo-Cosmétique*

Conclusions

- ✓ The efficacy results of this study demonstrate the benefit of this new gel cream emollient dedicated to the face in improving the long-term management of atopic skin condition.
- ✓ Its light texture combined with its very good tolerability could help to ensure long-term compliance.

Presented at the European Academy of Dermatology and Venereology Annual Congress, 30 September to 3 October 2026, Vienna, Austria